Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03404960
Recruitment Status : Recruiting
First Posted : January 19, 2018
Last Update Posted : June 10, 2021
Sponsor:
Collaborators:
Bristol-Myers Squibb
Tesaro, Inc.
Information provided by (Responsible Party):
University of Pennsylvania

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : June 2024